Details of the Drug Reposition

General Information of This Drug (ID: DM0C9IL)

Drug Name
Ranolazine   DM0C9IL
Synonyms
RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Angina pectoris DISCLMC4 BA40 Approved [1]
Acute coronary syndrome DIS7DYEW BA41 Approved [1]
Diarrhea-predominant irritable bowel syndrome DISD3GU2 DD91.01 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Paroxysmal atrial fibrillation DISD9JMI BC81.30 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Ranolazine FDA Label
2 Clinical pipeline report, company report or official report of Gilead.